Ascend Laboratories

Name

Ascend Laboratories

Legal name

Ascend Laboratories

Website

https://ascendlaboratories.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Generic pharmaceuticals
• FDA-approved medications
• Active pharmaceutical ingredients
• Prescription drug manufacturing
• Generic drug formulations

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Revenue generated from the sale of FDA-approved generic medications to healthcare providers, pharmacies, and distributors across the United States. The company offers prescription-only (Rx) products across 7 therapeutic categories.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Ascend Laboratories manufactures and sells 300+ FDA-approved generic prescription medications across 7 therapeutic categories, in dosage forms including tablets, capsules, creams, inhalation products, solutions, and suspensions. The company operates an end-to-end operation spanning in-house API manufacturing (acquired via Norac in 2016), FDA-cGMP compliant production, and distribution through U.S. pharmaceutical wholesale and pharmacy channels.

Product overview

Ascend Laboratories is a generic pharmaceutical company offering 300+ FDA-approved generic medications across 7 therapeutic categories. The product portfolio includes tablets, capsules, creams, inhalation products, solutions, and suspensions. Products are marketed under the company's proprietary label following FDA approvals, with patient assistance programs such as CoPay cards offered for select medications like Deferasirox Granules and Droxidopa Capsules.

Differentiator

Problem solved

Functional benefit

Products and services

• Amlodipine & Olmesartan Tablets Generic combination antihypertensive medication in tablet form, available in 5mg and 10mg dosage strengths, indicated for hypertension treatment.
• Amlodipine Besylate Tablets Generic calcium channel blocker for hypertension treatment, available in 2.5mg, 5mg, and 10mg dosage strengths.
• Aripiprazole Tablets Generic antipsychotic medication in tablet form, available in multiple dosage strengths including 2mg, 5mg, 10mg, 15mg, 20mg, and 30mg.
• Atorvastatin Tablets Generic HMG-CoA reductase inhibitor (statin) for cholesterol management, available in 10mg, 20mg, 40mg, and 80mg dosage strengths.
• Azathioprine Tablets Generic immunosuppressant medication in tablet form, 50mg dosage strength.
• Cefdinir Capsules Generic antibiotic in capsule form, available in 300mg, 125mg, and 250mg dosage strengths.
• Cefprozil Tablets Generic antibiotic in tablet form, available in 251mg and 250mg dosage strengths.
• Deferasirox Granules Generic iron chelator for treating iron overload, offered with a CoPay assistance card to support patient out-of-pocket costs.
• Droxidopa Capsules Generic medication indicated for orthostatic hypotension, offered with a CoPay assistance card to reduce patient costs.
• 2026 Generic Medications Portfolio Expansion Portfolio expansion of 15 new FDA-approved generic medications added to Ascend's U.S. product line in May 2026, raising the total SKU count above 300.

Quantifiable outcome

• 300+ FDA-approved generic medications available
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• AlkemcoreStrategic or Co-development Partner · 1 January 2012In 2010, Ascend Labs formed a strategic partnership with Alkem, an Indian pharmaceutical company. This partnership led to Ascend becoming Alkem's U.S. subsidiary in 2012, establishing Ascend as the U.S. presence for Alkem's pharmaceutical products. The partnership enabled Ascend to expand its generic pharmaceutical portfolio and leverage Alkem's product development capabilities.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Aurobindo Pharma USA: Aurobindo's US subsidiary is one of the largest Indian-affiliated generic manufacturers serving the US market with a similarly broad FDA-approved generic portfolio across multiple therapeutic categories and dosage forms. Direct comparable on model, parent backing, and US distribution strategy.
• Lupin Pharmaceuticals: Lupin is an India-headquartered generic drug maker with a major US commercial operation, offering FDA-approved generics across oral solids, injectables, and inhalation — directly comparable in product mix, regulatory posture, and strategic use of US subsidiaries to access the US market.
• Zydus Pharmaceuticals (USA): Zydus' US arm manufactures and distributes generic pharmaceuticals across therapeutic categories from India-parented operations, mirroring Ascend's positioning as an Indian-parent US generics subsidiary with FDA-approved SKUs and Broad therapeutic coverage.
• Dr. Reddy's Laboratories: Dr. Reddy's operates a large US generics business (including Promius Pharma) covering a broad portfolio of FDA-approved small-molecule generics and APIs — comparable on India-parented US generics strategy, vertical API integration, and broad therapeutic-category footprint.
• Glenmark Pharmaceuticals: Glenmark runs a US generics business with FDA-approved products across multiple therapeutic categories, comparable in distribution model (wholesaler-centric), target buyers, and reliance on parent-company pipeline feeding US operations.
• Amneal Pharmaceuticals: Amneal is a US-focused generic pharmaceutical manufacturer offering a broad portfolio of small-molecule generics across dosage forms and therapeutic categories, with vertically integrated manufacturing — directly comparable in scale, model, and channel relationships.
• Apotex Corp. Apotex is a major Canadian-based generic pharmaceutical company with substantial US operations, manufacturing and distributing FDA-approved generics across multiple therapeutic categories via wholesale and pharmacy channels.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with a massive US generics portfolio and well-established wholesale distribution — a broad incumbent that competes with Ascend across most of its therapeutic categories but at far greater scale and with branded specialty pharma alongside generics.
• Sandoz (Novartis): Sandoz is a global generics leader with a large US commercial presence (now independent of Novartis post-2023), offering broad FDA-approved generics across therapeutic categories. Larger and more diversified, but competes for the same wholesale-channel slots and pharmacy buyer relationships.
• Endo Pharmaceuticals: Endo operates a US generics business (Par Pharmaceutical) plus specialty branded products, competing in many of the same therapeutic categories as Ascend via the same wholesale distribution channels but at meaningfully larger scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Ascend-Laboratories-127133567373660

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascend Laboratories